Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
404-04-005 ISMRM Abstract

Brain iron varies with brain penetration capabilities of iron chelators: deferiprone vs deferasirox

Primary: Contrast Mechanisms - Susceptibility/QSM
Secondary: Neuro - Other Neurodegeneration
404-04-005 · Applications of QSM and Iron in the Brain · Tuesday, 12 May, 4:00 PM–5:50 PM · Ballroom East
Keywords: Blood brain barrier Quantitative Susceptibility Mapping (QSM) Iron quantification
Accepted
Carly Skudin1, Alexey Dimov2, Chao Li1,3,4, Sujit Sheth5, Yi Wang 2,6,7
1Department of Radiology, Weill Cornell Medicine, New York, United States of America
2Radiology, Weill Cornell Medicine, New York, United States of America
3Weill Cornell Medicine, New York, United States of America
4Applied and Engineering Physics, Cornell University, Ithaca, United States of America
5Pediatrics, Weill Cornell Medicine, New York, United States of America
6Biomedical Engineering, Cornell University, Ithaca, United States of America
7Department Radiology & Biomedical Engineering, Weill Cornell Medicine, Cornell University, New York, United States of America
Presenting Author: Yi Wang

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Brittenham GM. Chapter 35 - Pathophysiology of Iron Homeostasis. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology (Seventh Edition).Elsevier; 2018:468-477
2. Botzenhardt S, Li N, Chan EW, Sing CW, Wong IC, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol. Mar 2017;98(3):198-217. doi:10.1111/ejh.12833 [doi]
3. Diaz-Garcia JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Nino MD, Villarrubia J, Ortiz A. Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol. Oct 2014;10(10):574-86. doi:10.1038/nrneph.2014.121 [doi]
4. Martin-Sanchez D, Gallegos-Villalobos A, Fontecha-Barriuso M, et al. Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. Sci Rep. Jan 31 2017;7:41510. doi:10.1038/srep41510 [doi]
5. Martin-Bastida A, Ward RJ, Newbould R, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Sci Rep. May 3 2017;7(1):1398. doi:10.1038/s41598-017-01402-2 [doi]
6. Ayton S, Barton D, Brew B, et al. Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. Jan 1 2025;82(1):11–18. doi:10.1001/jamaneurol.2024.3733 [doi]
7. Liu Z, Spincemaille P, Yao Y, Zhang Y, Wang Y. MEDI+0: Morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping. Magn Reson Med. May 2018;79(5):2795–2803. doi:10.1002/mrm.26946 [doi]
8. Liu T, Khalidov I, de Rochefort L, et al. A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed. Nov 2011;24(9):1129–36. doi:10.1002/nbm.1670 [doi]
9. Roberts AG, Romano DJ, Sisman M, et al. Maximum spherical mean value filtering for whole-brain QSM. Magn Reson Med. Apr 2024;91(4):1586–1597. doi:10.1002/mrm.29963 [doi]
10. Avants BB, Yushkevich P, Pluta J, Minkoff D, Korczykowski M, Detre J, Gee JC. The optimal template effect in hippocampus studies of diseased populations. Neuroimage. Feb 1 2010;49(3):2457-66. doi:10.1016/j.neuroimage.2009.09.062 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/404-04-005